Despite a tad soft Q1 FY19, Eurofins remains confident in achieving its full-year financial targets. Though clinical diagnostic business’ problems continued in the quarter (regulatory headwinds in the US and France), Food and Environment testing segments remained healthy. No material change in our financial estimates. Our stock recommendation ‘Add’ is likely to be maintained.
26 Apr 2019
Regulatory changes continue to trouble
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Regulatory changes continue to trouble
Eurofins Scientific SE (ESF:WBO) | 0 0 1.6% | Mkt Cap: 8,723m
- Published:
26 Apr 2019 -
Author:
Mohit Rathi -
Pages:
2
Despite a tad soft Q1 FY19, Eurofins remains confident in achieving its full-year financial targets. Though clinical diagnostic business’ problems continued in the quarter (regulatory headwinds in the US and France), Food and Environment testing segments remained healthy. No material change in our financial estimates. Our stock recommendation ‘Add’ is likely to be maintained.